Cargando…

Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective

Biologicals revolutionized the treatment of Rheumatoid Arthritis (RA). The targeted suppression of key inflammatory pathways involved in joint inflammation and destruction allows better disease control, which, however, comes at the price of an elevated infection risk due to relative immunosuppressio...

Descripción completa

Detalles Bibliográficos
Autor principal:	Keyser, Filip De
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers Ltd 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182090/ https://www.ncbi.nlm.nih.gov/pubmed/22081766 http://dx.doi.org/10.2174/157339711794474620

Ejemplares similares

Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumatoid Arthritis
por: Janssens, Xavier, et al.
Publicado: (2016)

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
por: Delabaye, Isabelle, et al.
Publicado: (2010)

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
por: Niccoli, Laura, et al.
Publicado: (2018)

Switching of biological therapies in Brazilian patients with rheumatoid arthritis
por: de Lucena Valim, Juliana Miranda, et al.
Publicado: (2018)

Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
por: Furer, Victoria, et al.
Publicado: (2023)

The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies
por: Eddaoudi, Meryem, et al.
Publicado: (2021)

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity
por: Vander Cruyssen, Bert, et al.
Publicado: (2010)

Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment
por: Vass, Caroline M, et al.
Publicado: (2021)

Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective
por: Bolge, Susan C, et al.
Publicado: (2015)

Assessment of Activity Limitations with the Health Assessment Questionnaire Predicts the Need for Support Measures in Patients with Rheumatoid Arthritis: A Multicenter Observational Study
por: Janssens, Xavier, et al.
Publicado: (2014)

A Systematic Review of Discrete Choice Experiment Studies in Rheumatoid Arthritis Biological Medicines
por: Zartab, Saman, et al.
Publicado: (2021)

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
por: Findeisen, Kate E, et al.
Publicado: (2021)

93. Recurrent infections in a patient treated with biologic therapy for seropositive rheumatoid arthritis
por: Jubber, Ameen, et al.
Publicado: (2018)

Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy
por: Barton, Jennifer L
Publicado: (2009)

The efficiency of biologic therapy in a group of patients with rheumatoid arthritis
por: Gavrilă, BI, et al.
Publicado: (2015)

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
por: Mishra, Richa, et al.
Publicado: (2009)

Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis
por: Novella-Navarro, Marta, et al.
Publicado: (2020)

Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
por: Trang, D. A. M. Thuy, et al.
Publicado: (2021)

Rationale of using different biological therapies in rheumatoid arthritis
por: Geyer, Matthias, et al.
Publicado: (2010)

Wnt Signaling and Biological Therapy in Rheumatoid Arthritis and Spondyloarthritis
por: Cici, Daniela, et al.
Publicado: (2019)

Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis
por: Lopez-Pedrera, Chary, et al.
Publicado: (2020)

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies
por: Vander Cruyssen, Bert, et al.
Publicado: (2010)

Citrullinated vimentin as an important antigen in immune complexes from synovial fluid of rheumatoid arthritis patients with antibodies against citrullinated proteins
por: Van Steendam, Katleen, et al.
Publicado: (2010)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
por: Jin, Yinzhu, et al.
Publicado: (2017)

Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies
por: Fischer, Peter A, et al.
Publicado: (2018)

Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'
por: Vander Cruyssen, Bert, et al.
Publicado: (2006)

Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis
por: Kruithof, Elli, et al.
Publicado: (2005)

Patient’s perspective of sustained remission in rheumatoid arthritis
por: Contreras-Yáñez, Irazú, et al.
Publicado: (2017)

Perspectives of Glucocorticoid Use in Patients with Rheumatoid Arthritis
por: Venter, Gabriella, et al.
Publicado: (2021)

REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients
por: González-Álvaro, Isidoro, et al.
Publicado: (2017)

Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use
por: Hazes, Johanna M.W., et al.
Publicado: (2011)

Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy
por: Chen, Yi-Ming, et al.
Publicado: (2018)

Characterization of T-Cell Receptor Repertoire in Patients with Rheumatoid Arthritis Receiving Biologic Therapies
por: Chang, Che-Mai, et al.
Publicado: (2019)

Applying science in practice: the optimization of biological therapy in rheumatoid arthritis
por: Ramiro, Sofia, et al.
Publicado: (2010)

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2018)

What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?
por: Humphreys, Jenny, et al.
Publicado: (2016)

Predictive model to identify multiple failure to biological therapy in patients with rheumatoid arthritis
por: Novella-Navarro, Marta, et al.
Publicado: (2022)

Usefulness of Cytokine Gene Polymorphisms for the Therapeutic Choice in Japanese Patients with Rheumatoid Arthritis
por: Tsujimoto, Saki, et al.
Publicado: (2021)

Evaluating quality of care in rheumatoid arthritis: the patient perspective
por: Mahmood, Sehrash, et al.
Publicado: (2017)

Treatment with Biologicals in Rheumatoid Arthritis: An Overview
por: Rein, Philipp, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ppbico65qp7en571hk85vgv0id